The chief executive of the drugmaker Novo Nordisk, Lars Fruergaard Jørgensen, is scheduled to face tough questions Tuesday on Capitol Hill about the high costs of the company’s widely popular weight-loss drugs.
Jørgensen will appear before the Senate Committee on Health, Education, Labor and Pensions during a livestreamed hearing Tuesday starting at 10 a.m. ET.
The head of the committee, Sen. Bernie Sanders, I-Vt., has been vocal about his frustrations over how much Novo Nordisk charges Americans for both Ozempic (used to treat type 2 diabetes) and Wegovy (approved for weight loss).
“In general, we pay by far the highest prices in the world for prescription drugs. Same exact medicine sold in Canada, Europe is a fraction of what it is in the United States,” Sanders said in an interview Monday. “The result of that is that hundreds of thousands of people in this country who desperately need this product will not be able to afford it.”
Greed is first, as the greed is why food labeling isn’t as clear as other countries because that would get in the way of profits. Then add in massive portions to get people in restaurant seats, rampant poverty due to policies that make food choice unaffordable for many, and the cultural glorification of excess and it becomes a less about self control and more about how hard it is to fight the cultural pressures that lead to obesity.
Agreed, and making a drug whose side effects are being touted more than the condition it was designed for won’t make it any better.